<DOC>
	<DOCNO>NCT02928224</DOCNO>
	<brief_summary>This multicenter , randomize , open-label , 3-arm Phase 3 study evaluate encorafenib + cetuximab plus minus binimetinib versus Investigator 's choice either irinotecan/cetuximab FOLFIRI/cetuximab , control , patient BRAFV600E mCRC whose disease progress 1 2 prior regimen metastatic setting . The study contain Safety Lead-in Phase safety tolerability encorafenib + binimetinib + cetuximab assess prior Phase 3 portion study .</brief_summary>
	<brief_title>Study Encorafenib + Cetuximab Plus Minus Binimetinib vs. Irinotecan/Cetuximab Infusional 5-Fluorouracil ( 5-FU ) /Folinic Acid ( FA ) /Irinotecan ( FOLFIRI ) /Cetuximab With Safety Lead-in Encorafenib + Binimetinib + Cetuximab Patients With BRAF V600E-mutant Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Key Age ≥ 18 year time inform consent Histologically cytologicallyconfirmed CRC metastatic Presence BRAFV600E tumor tissue previously determine local assay time prior Screening central laboratory Progression disease 1 2 prior regimen metastatic set Evidence measurable evaluable nonmeasurable disease per RECIST , v1.1 Adequate bone marrow , cardiac , kidney liver function Able take oral medication Female patient either postmenopausal least 1 year , surgically sterile least 6 week , must agree take appropriate precaution avoid pregnancy screen followup childbearing potential Males must agree take appropriate precaution avoid father child screen followup Key Prior treatment RAF inhibitor , MEK inhibitor , cetuximab , panitumumab EGFR inhibitor Prior irinotecan hypersensitivity toxicity would suggest inability tolerate irinotecan 180 mg/m2 every 2 week Symptomatic brain metastasis leptomeningeal disease History current evidence retinal vein occlusion current risk factor retinal vein occlusion ( e.g. , uncontrolled glaucoma ocular hypertension , history hyperviscosity hypercoagulability syndrome ) Known history acute chronic pancreatitis History chronic inflammatory bowel disease Crohn 's disease require medical intervention ( immunomodulatory immunosuppressive medication surgery ) ≤12 month prior randomization Uncontrolled blood pressure despite medical treatment Impaired GI function disease may significantly alter absorption encorafenib binimetinib ( e.g. , ulcerative disease , uncontrolled vomiting , malabsorption syndrome , small bowel resection decrease intestinal absorption ) Concurrent previous malignancy within 5 year study entry , except cure basal squamous cell skin cancer , superficial bladder cancer , prostate intraepithelial neoplasm , carcinoma insitu cervix , noninvasive indolent malignancy History thromboembolic cerebrovascular event ≤ 6 month prior start study treatment , include transient ischemic attack , cerebrovascular accident , deep vein thrombosis pulmonary embolus Concurrent neuromuscular disorder associate potential elevate CK ( e.g. , inflammatory myopathy , muscular dystrophy , amyotrophic lateral sclerosis , spinal muscular atrophy ) Residual CTCAE ≥ Grade 2 toxicity prior anticancer therapy , exception Grade 2 alopecia Grade 2 neuropathy Known history HIV infection Active hepatitis B hepatitis C infection Known history Gilbert 's syndrome Known contraindication receive cetuximab irinotecan plan dos</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>BRAF</keyword>
	<keyword>BRAFV600E</keyword>
</DOC>